Sangamo Therapeutics, Inc.
Common Stock · USD · OTC
Price
$0.204
Cap
$3.17B
Earnings
—
30d Trend
+6.5%
BRAIN47 SIGNAL
Raw weighted: 27×Macro 0.99 (−1%)=27
RISK
QUALITY
MOMENTUM
TECHNICAL
FUNDAMENTALS
Macro: neutral (×0.99) - Fear/Greed: 65 (Greed) - Data: 100%
BRAIN47 HORIZON ANALYSIS
Limited short-term thesis
BRAIN47'S ASSESSMENT
I rate Sangamo Therapeutics, Inc. at 27/100 — a VERY WEAK reading on the Brain47 Signal. The strongest factor is fundamentals at 75/100. I classify this as a speculative position with the strongest thesis on a short-term horizon.
DETAILED ANALYSIS
Limited short-term thesis. Fundamentals (75) and Technical (43) are the primary strengths. I note that momentum is the weakest area at 13/100 — this warrants monitoring. I classify this as a speculative position — elevated volatility at 194% and smaller market cap define the opportunity.
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.